Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mel Spigelman

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinics in Chest Medicine|April 20, 2005
New drugs for tuberculosis: current status and future prospectsRichard J O'Brien, Mel Spigelman
The New England Journal of Medicine|November 30, 2012
Multidrug-resistant tuberculosisMel Spigelman, Carolyn Compton, Jan Gheuens, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 22, 2010
New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decadesMel Spigelman, Raymond Woosley, Jan Gheuens
The Journal of Infectious Diseases|March 27, 2012
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the futureChristian Lienhardt, Mario Raviglione, Mel Spigelman, et al.
Bulletin of the World Health Organization|May 3, 2023
Collaborations between product development partnerships and the World Health OrganizationMatthias Helble, Tanja Kuchenmüller, John Reeder, et al.
Antimicrobial Agents and Chemotherapy|October 20, 2020
An Exposure-Response Perspective on the Clinical Dose of PretomanidJerry R Nedelman, David H Salinger, Vishak Subramoney, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinics in Chest Medicine|April 20, 2005
New drugs for tuberculosis: current status and future prospectsRichard J O'Brien, Mel Spigelman
The New England Journal of Medicine|November 30, 2012
Multidrug-resistant tuberculosisMel Spigelman, Carolyn Compton, Jan Gheuens, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|May 22, 2010
New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decadesMel Spigelman, Raymond Woosley, Jan Gheuens
The Journal of Infectious Diseases|March 27, 2012
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the futureChristian Lienhardt, Mario Raviglione, Mel Spigelman, et al.
Bulletin of the World Health Organization|May 3, 2023
Collaborations between product development partnerships and the World Health OrganizationMatthias Helble, Tanja Kuchenmüller, John Reeder, et al.
Antimicrobial Agents and Chemotherapy|October 20, 2020
An Exposure-Response Perspective on the Clinical Dose of PretomanidJerry R Nedelman, David H Salinger, Vishak Subramoney, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 1